Intravitreal bevacizumab to facilitate vitrectomy in idiopathic ischaemic retinal vasculitis.
To describe the use of intravitreal bevacizumab in idiopathic retinal vasculitis prior to vitrectomy and delamination. A young healthy male presented with idiopathic retinal vasculitis. His condition was refractory to panretinal photocoagulation and systemic steroids. The progression of his condition necessitated vitrectomy and delamination. Intravitreal bevacizumab was used to facilitate the surgical procedure, with effective results. Intravitreal bevacizumab can be an adjunct to vitrectomy in idiopathic retinal vasculitis. However, caution must be taken due to its ability to promote fibrosis and to produce further tractional and/or rhegmatogenous retinal detachment. Further controlled studies are required to understand its benefits in managing complicated idiopathic retinal vasculitis.
Wong
Roger
R
Vitreoretinal Service, Guy's and St. Thomas' Hospital NHS Foundation Trust, Ophthalmology Department, St. Thomas' Hospital, Lambeth Palace Road, London, SE1 2PD, United Kingdom. drrogerwong@aol.com
Gupta
Bhaskar
B
Stanford
Miles R
MR
Laidlaw
D Alistair H
DA
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D018450:Disease Progression; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D006801:Humans; D056965:Injections, Intraocular; D007511:Ischemia / Q000150:complications*; D008297:Male; D011184:Postoperative Period; D011300:Preoperative Care; D031300:Retinal Vasculitis / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000601:surgery*; D012171:Retinal Vessels; D014792:Visual Acuity; D014821:Vitrectomy / Q000009:adverse effects; D014822:Vitreous Body; D014823:Vitreous Hemorrhage / Q000175:diagnosis / Q000209:etiology / Q000601:surgery
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab